Clinical Trials Logo
  1. Home
  2. Complex Regional Pain Syndrome
  3. NCT03990649

Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)

Complex Regional Pain Syndrome Clinical Trial

Official title:
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome

Clinical Trial Summary

The purpose of this study is to investigate the effect of soticlestat (TAK-935) on calculated 24-hour average pain intensity by the numeric pain scale (NPS).

Clinical Trial Description

The drug being tested in this study is called soticlestat (TAK-935). Soticlestat is being tested to treat people with chronic complex regional pain syndrome (CRPS). This study will look at the efficacy, safety, and tolerability of soticlestat as an adjunctive therapy in participants with CRPS. The study will enroll approximately 24 patients. Participants will be randomly assigned (by chance, like flipping a coin) in 2:1 ratio to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need): Soticlestat 100 mg tablets, 100, 200 or 300 mg twice daily (BID) Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient Participants will receive 100 mg soticlestat tablets or soticlestat matching placebo tablets, BID for Week 1, 2x100 mg soticlestat tablets or soticlestat matching placebo tablets, BID for Week 2 and followed by 3x100 mg soticlestat tablets or soticlestat matching placebo tablets, BID for Week 3. Dose will be uptitrated based on safety and tolerability in titration period. Participants will continue to receive the same dose in maintenance period. Dose adjustments during maintenance period may take place due to safety and tolerability. Participants will then enter Part B (optional) or taper period. In Part B all participants will receive soticlestat 2x100 mg tablets, BID for 1 Week, followed by soticlestat 3x100 mg tablets, BID for 1 Week. Dose will be uptitrated/downtitrated based on safety and tolerability in titration period (Part B), participants will continue to receive the same dose in maintenance period (Part B) and followed by a taper period. This multi-center trial will be conducted in United Kingdom. The overall time to participate in this study is approximately 36 weeks. Participants will make multiple visits to the clinic and will be contacted by telephone 15 days after last dose of study drug for a follow-up assessment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03990649
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 2
Start date July 23, 2019
Completion date October 28, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02753335 - A Comparison of Two Treatments for CRPS and Changes in Resting-State Connectivity of Cerebral Networks. N/A
Recruiting NCT01134289 - Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block Phase 3
Completed NCT00579085 - Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS Phase 2
Completed NCT02837822 - Effects of Spinal Cord Stimulation on Sensory Perceptions of Chronic Pain Patients N/A
Completed NCT02070367 - Somatosensory Assessment and Rehabilitation of Allodynia (SARA) N/A
Completed NCT00462566 - The Efficacy of Motor Cortex Stimulation for Pain Control N/A
Active, not recruiting NCT03228160 - Light Irradiation and Outcome for Neuropathic Pain N/A
Terminated NCT02094352 - Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome Phase 2
Recruiting NCT02502162 - Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome N/A
Recruiting NCT06393101 - The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome Early Phase 1
Recruiting NCT03616262 - "Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome" Early Phase 1
Active, not recruiting NCT02504008 - CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 Phase 3
Completed NCT03879538 - Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome Phase 3
Terminated NCT03794024 - Comparison of Dorsal Column Stimulation to Dorsal Root Ganglion Stimulation for Complex Regional Pain Syndrome
Terminated NCT00780390 - Autonomic Dysfunction and Spinal Cord Stimulation in Complex Regional Pain Syndrome N/A
Completed NCT00904202 - A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Phase 4
Recruiting NCT05197959 - Treatment of Complex Regional Pain Syndrome N/A
Completed NCT02753101 - [18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica Early Phase 1
Withdrawn NCT00414804 - Spinal Cord Stimulation Versus Nerve Blocks and Physical Therapy N/A
Completed NCT02972359 - Safety of Intravenous Neridronic Acid in CRPS Phase 3